My Thoughts on New Findings in Lung Cancer From WCLC 2019
  • CME

September 7-10, 2019; Barcelona, Spain
New clinical data in lung cancer are emerging with the potential to change clinical practice. In this commentary, I discuss top studies on both immunotherapies and novel targeted agents that were presented at WCLC 2019.
Suresh S. Ramalingam, MD
Physicians: maximum of 0.4 AMA PRA Category 1 Credits
Released: September 26, 2019 Expiration: September 25, 2020

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Apply recently presented data to clinical practice to expand treatment options and improve outcomes for patients with lung cancer
  • Identify subpopulations of patients with lung cancer most likely to benefit from a specific treatment plan based on prognostic or predictive markers
  • Discuss new data on novel agents and therapeutic approaches for patients with lung cancer
  • Consider how new trial findings might affect treatment of lung cancer clinical practice in the future

Acknowledgements

Provided by Clinical Care Options, LLC

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA

Sophia Kelley
(203)-316-2125
skelley@clinicaloptions.com
www.clinicaloptions.com

Supported by an educational grant from
Bristol-Myers Squibb

Information on this Educational Activity

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any relevant conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:

Faculty

Suresh S. Ramalingam, MD

Professor of Hematology and Medical Oncology
Roberto C. Goizueta Chair for Cancer Research
Director,
Division of Medical Oncology
Assistant Dean for Cancer Research
Emory University School of Medicine
Deputy Director, Winship Cancer Institute
Atlanta, Georgia

Suresh S. Ramalingam, MD, has disclosed that he has received consulting fees from Amgen, AstraZeneca, Bristol-Myers Squibb, Genentech, Loxo, Merck, Nektar, Tesaro, and Takeda and funds for research support from AstraZeneca, Bristol-Myers Squibb, Merck, and Syndax.

Staff

Bing-e Xu, PhD

Scientific Director

Bing-E Xu, PhD, has no relevant conflicts of interest to report.
Gordon Kelley

Senior Clinical Editor

Gordon Kelley has no relevant conflicts of interest to report.
Timothy A. Quill, PhD

Associate Director, Scientific Services

Timothy A. Quill, PhD, has no relevant conflicts of interest to report.
Kevin Obholz, PhD

Senior Director, Educational Strategy

Kevin Obholz, PhD, has no relevant conflicts of interest to report.
Katie Eustace, MBA

Senior Director, Global Medical Education, Europe

Katie Eustace has no relevant conflicts of interest to report.
Tina B. Stacy, PharmD, FACEHP, BCOP, CHCP

Executive Vice President, Educational Strategy
General Manager, Oncology

Tina B. Stacy, PharmD, FACEHP, BCOP, CHCP, has no relevant conflicts of interest to report.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Target Audience

This program is intended for medical oncologists and other healthcare providers who care for patients with lung cancer.

Goal

The goal of this activity is to improve learners’ understanding of how to optimally apply recent practice-changing findings in the treatment of patients with lung cancer.

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation

CCO designates this enduring material for a maximum of 0.4 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Program Medium

This program has been made available online.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 0.4 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from September 26, 2019, through September 25, 2020:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 100% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Related Content

Downloadable slides with key data from the 2019 ESMO Congress created by Clinical Care Options.

Axel Grothey Headshot Axel Grothey, MD Sara Hurvitz, MD, FACP Bradley J. Monk, MD, FACS, FACOG Sandip P. Patel, MD Released: October 10, 2019

CME-certified on-demand Webcast of a CCO symposium at ASCP 2019 featuring expert perspectives on predictive biomarkers for immune checkpoint inhibitors in lung cancer

H. Jack West, MD
Program Director
person default Sanjay Mukhopadhyay, MD Sandip P. Patel, MD
Physicians: maximum of 1.0 AMA PRA Category 1 Credit Released: October 8, 2019 Expiration: October 7, 2020

Get a preview of key expert selected studies at ESMO 2019 in breast, gastrointestinal, gynecologic, and thoracic malignancies from Clinical Care Options

Axel Grothey Headshot Axel Grothey, MD Sara Hurvitz, MD, FACP Bradley J. Monk, MD, FACS, FACOG Sandip P. Patel, MD Released: September 26, 2019

In this slideset, Sandip P. Patel, MD, reviews emerging predictors of response to checkpoint inhibitors in lung cancer.

Sandip P. Patel, MD Released: September 11, 2019

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Welcome to the CCO site.

You are accessing CCO's educational content today as a Guest user.

If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.

Continue

More info

CCO’s educational programs are available completely free of charge on the ClinicalOptions.com, inPractice.com, and inPracticeAfrica.com Web sites. Certain features and functions are restricted for Guest users. By consenting to become a full member, you are eligible to receive CME/CE credit or participation certificates from certified activities, to register for CCO’s free live meetings and webinars, and to receive CCO’s email newsletters alerting you to new content. You can unsubscribe from our emails at any time. CCO strictly protects the privacy of our members, according to our privacy policy.

A confirmation email will be sent to . Not You?